Abivax (NASDAQ:ABVX) Issues Quarterly Earnings Results

Abivax (NASDAQ:ABVX) released its quarterly earnings data on Monday. The company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79), Zacks reports. The company had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.80 million.

Abivax Stock Down 5.0%

Shares of NASDAQ:ABVX opened at $98.29 on Wednesday. The firm has a market cap of $8.59 billion, a P/E ratio of -16.22 and a beta of 0.96. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83. The business has a fifty day simple moving average of $120.03 and a 200 day simple moving average of $117.54.

Key Headlines Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax reported €402.4 million in cash, cash equivalents and short-term investments as of June 30, supplemented by €767.1 million in net proceeds from its July offering. Management said the funding extends its cash runway into the fourth quarter of 2029 and supports future commercialization efforts. Abivax Presents Business Updates and First Half 2026 Financial Results
• Positive Sentiment: The company plans to submit a new drug application for obefazimod in ulcerative colitis by the end of 2026, providing a key upcoming catalyst for the clinical-stage biotech.
• Positive Sentiment: Barclays reaffirmed its “overweight” rating and set a $148 price target, while Truist maintained a “buy” rating with a $151 target. Both targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Abivax appointed Chris Rabbat as chief medical officer, succeeding Fabio Cataldi, and named Tim Kelly chief technical officer to lead manufacturing, quality and information technology functions. The changes are intended to support regulatory and commercial-readiness activities. Abivax Says Chris Rabbat to Succeed Fabio Cataldi as Chief Medical Officer
• Negative Sentiment: Second-quarter earnings were weaker than expected: Abivax posted a loss of $1.71 per share versus the consensus loss estimate of $0.92. Revenue of $1.37 million exceeded expectations, but the sizable EPS miss and wider first-half net loss increased investor concerns about ongoing cash burn.
• Negative Sentiment: Wedbush lowered its price target from $140 to $118 and adopted a “neutral” rating, signaling more cautious expectations despite the target remaining above the stock’s recent level.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Piper Sandler increased their price target on Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. The Goldman Sachs Group started coverage on Abivax in a research report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price target on the stock. Truist Financial decreased their price target on shares of Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a research note on Tuesday. Guggenheim reissued a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $156.69.

About Abivax

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.